Novo Nordisk Pharmatech A/S is a pharmaceutical company that has been a part of the Novo Nordisk pharmaceutical group since it was acquired in 1986. Specializing in diabetes care and healthcare, Novo Nordisk Pharmatech is a global leader in the biopharmaceutical and pharmaceutical industries. They offer a range of innovative products, including recombinant insulin for cell growth media and pharmaceutical grade quaternary ammonium compounds (Quats).

Their products are known for their high quality, extensive manufacturing and quality control, regulatory documentation, precision delivery, and comprehensive risk mitigation strategy. With a mission to enable better medicines and better lives, Novo Nordisk Pharmatech is committed to providing sustainable pharmaceutical materials through customized solutions. They operate globally with headquarters and manufacturing in Denmark, branch offices in Singapore and Boston, USA, and a distribution center in Indianapolis, USA.

The company follows The Novo Nordisk Way, a set of guiding principles that reflects their commitment to patients, employees, and shareholders. By balancing financial, social, and environmental considerations, Novo Nordisk Pharmatech strives to make a positive impact on society while delivering competitive financial results